CAJ | 학술논문

新辅助放化疗目前已成为临床Ⅱ、Ⅲ期直肠癌的标准辅助治疗方式。接受新辅助治疗的患者部分可达到病理完全缓解，即切除的样本中不存在癌细胞。达到临床完全缓解的患者，取消手术治疗后仍获得较好的生存率。临床是否可以通过筛选取消部分患者的手术治疗，以避免术中及术后可能存在的风险及不良反应成为值得探讨的问题。
신보조방화료목전이성위림상Ⅱ、Ⅲ기직장암적표준보조치료방식。접수신보조치료적환자부분가체도병리완전완해，즉절제적양본중불존재암세포。체도림상완전완해적환자，취소수술치료후잉획득교호적생존솔。림상시부가이통과사선취소부분환자적수술치료，이피면술중급술후가능존재적풍험급불량반응성위치득탐토적문제。
Neoadjuvant chemoradiotherapy has been used as a standard treatment for patients with locally advanced (T2 and T3 ) rectal carcinoma. Some patients who receive neoadjuvant chemoradiotherapy obtain pathological complete remission, namely, the absence of any tumor cells in the surgical specimens. The patients who obtain pathological complete remission get a better survival rate after canceling operation. Researches are still needed to investigate whether it is safe for patients in order to avoid risk and adverse reaction.